Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.

Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, Frigerio S, Servida M, Cuppini L, Antozzi C, Cuzzubbo S, Corbetta C, Paterra R, Acerbi F, Ferroli P, DiMeco F, Fariselli L, Parati EA, Bruzzone MG, Finocchiaro G.

Oncoimmunology. 2018 Jan 29;7(4):e1412901. doi: 10.1080/2162402X.2017.1412901. eCollection 2018.

2.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184
3.

Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.

Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, D'Ambrosio A, Comoglio PM, Finocchiaro G, Boccaccio C.

Stem Cells. 2017 Nov;35(11):2218-2228. doi: 10.1002/stem.2703. Epub 2017 Sep 29.

PMID:
28895245
4.

Hypermutations in gliomas: a potential immunotherapy target.

Finocchiaro G, Langella T, Corbetta C, Pellegatta S.

Discov Med. 2017 Feb;23(125):113-120. Review.

5.

ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.

Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazi M, Dietrich PY, Walker PR, Martinvalet D.

EMBO J. 2017 Jun 1;36(11):1493-1512. doi: 10.15252/embj.201695429. Epub 2017 Mar 10.

6.

Resetting cancer stem cell regulatory nodes upon MYC inhibition.

Galardi S, Savino M, Scagnoli F, Pellegatta S, Pisati F, Zambelli F, Illi B, Annibali D, Beji S, Orecchini E, Alberelli MA, Apicella C, Fontanella RA, Michienzi A, Finocchiaro G, Farace MG, Pavesi G, Ciafrè SA, Nasi S.

EMBO Rep. 2016 Dec;17(12):1872-1889. Epub 2016 Nov 16.

7.

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, Boehler M, Calvo Tardón M, Jueliger S, Taverna P, Barba L, Marinari E, Pellegatta S, Bassoy EY, Martinvalet D, Dietrich PY, Walker PR.

PLoS One. 2016 Aug 31;11(8):e0162105. doi: 10.1371/journal.pone.0162105. eCollection 2016.

8.

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma.

Pessina S, Cantini G, Kapetis D, Cazzato E, Di Ianni N, Finocchiaro G, Pellegatta S.

Oncoimmunology. 2015 Oct 29;5(5):e1108513. doi: 10.1080/2162402X.2015.1108513. eCollection 2016 May.

9.

MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.

De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, Reato G, Pellegatta S, Finocchiaro G, Perera T, Garibaldi E, Gabriele P, Comoglio PM, Boccaccio C.

EMBO Mol Med. 2016 May 2;8(5):550-68. doi: 10.15252/emmm.201505890. Print 2016 May.

10.

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies.

Finocchiaro G, Pellegatta S.

Cancer Immunol Immunother. 2016 Jan;65(1):101-9. doi: 10.1007/s00262-015-1754-9. Epub 2015 Sep 16. Review.

PMID:
26377689
11.

Novel mechanisms and approaches in immunotherapy for brain tumors.

Finocchiaro G, Pellegatta S.

Discov Med. 2015 Jul-Aug;20(108):7-15. Review.

12.

Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.

Nava S, Lisini D, Pogliani S, Dossena M, Bersano A, Pellegatta S, Parati E, Finocchiaro G, Frigerio S.

Stem Cells Transl Med. 2015 Oct;4(10):1164-72. doi: 10.5966/sctm.2015-0091. Epub 2015 Aug 13.

13.

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.

Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G.

Acta Neuropathol Commun. 2015 Jan 21;3:4. doi: 10.1186/s40478-014-0180-0.

14.

EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.

Cominelli M, Grisanti S, Mazzoleni S, Branca C, Buttolo L, Furlan D, Liserre B, Bonetti MF, Medicina D, Pellegrini V, Buglione M, Liserre R, Pellegatta S, Finocchiaro G, Dalerba P, Facchetti F, Pizzi M, Galli R, Poliani PL.

J Natl Cancer Inst. 2015 Mar 3;107(5). pii: djv041. doi: 10.1093/jnci/djv041. Print 2015 May.

PMID:
25739547
15.

Perspectives for immunotherapy in glioblastoma treatment.

Finocchiaro G, Pellegatta S.

Curr Opin Oncol. 2014 Nov;26(6):608-14. doi: 10.1097/CCO.0000000000000135. Review.

PMID:
25210870
16.

Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.

Favaro R, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E, Pisati F, Ottolenghi S, Foti M, Finocchiaro G, Malatesta P, Nicolis SK.

Cancer Res. 2014 Mar 15;74(6):1833-44. doi: 10.1158/0008-5472.CAN-13-1942. Epub 2014 Mar 5.

17.

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.

Patanè M, Porrati P, Bottega E, Morosini S, Cantini G, Girgenti V, Rizzo A, Eoli M, Pollo B, Sciacca FL, Pellegatta S, Finocchiaro G.

Mol Cancer. 2013 Dec 11;12:160. doi: 10.1186/1476-4598-12-160.

18.

Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M.

PLoS One. 2013 Sep 12;8(9):e74345. doi: 10.1371/journal.pone.0074345. eCollection 2013.

19.

DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT.

Schneider L, Pellegatta S, Favaro R, Pisati F, Roncaglia P, Testa G, Nicolis SK, Finocchiaro G, d'Adda di Fagagna F.

Stem Cell Reports. 2013 Jul 25;1(2):123-38. doi: 10.1016/j.stemcr.2013.06.004. eCollection 2013.

20.

The integrated landscape of driver genomic alterations in glioblastoma.

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A.

Nat Genet. 2013 Oct;45(10):1141-9. doi: 10.1038/ng.2734. Epub 2013 Aug 5.

21.

FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration.

Frattini V, Pisati F, Speranza MC, Poliani PL, Frigé G, Cantini G, Kapetis D, Cominelli M, Rossi A, Finocchiaro G, Pellegatta S.

Oncotarget. 2012 Sep 22;3(10):1146-57. Print 2012 Oct.

22.

The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.

Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, Nava S, Anghileri E, Cuppini L, Cuccarini V, Ciusani E, Dossena M, Pollo B, Mantegazza R, Parati EA, Finocchiaro G.

Oncoimmunology. 2013 Mar 1;2(3):e23401.

23.

An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.

Nava S, Dossena M, Pogliani S, Pellegatta S, Antozzi C, Baggi F, Gellera C, Pollo B, Parati EA, Finocchiaro G, Frigerio S.

PLoS One. 2012;7(12):e52301. doi: 10.1371/journal.pone.0052301. Epub 2012 Dec 20.

24.

A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells.

De Rosa A, Pellegatta S, Rossi M, Tunici P, Magnoni L, Speranza MC, Malusa F, Miragliotta V, Mori E, Finocchiaro G, Bakker A.

PLoS One. 2012;7(12):e52113. doi: 10.1371/journal.pone.0052113. Epub 2012 Dec 21.

25.

Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity.

Cantini G, Pisati F, Pessina S, Finocchiaro G, Pellegatta S.

Oncoimmunology. 2012 Sep 1;1(6):884-893.

26.

NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma.

Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M, Pellegatta S, Finocchiaro G.

Oncotarget. 2012 Jul;3(7):723-34.

27.

Transforming fusions of FGFR and TACC genes in human glioblastoma.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A.

Science. 2012 Sep 7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.

28.

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C.

Cancer Res. 2012 Sep 1;72(17):4537-50. doi: 10.1158/0008-5472.CAN-11-3490. Epub 2012 Jun 26.

29.

Rai is a new regulator of neural progenitor migration and glioblastoma invasion.

Ortensi B, Osti D, Pellegatta S, Pisati F, Brescia P, Fornasari L, Levi D, Gaetani P, Colombo P, Ferri A, Nicolis S, Finocchiaro G, Pelicci G.

Stem Cells. 2012 May;30(5):817-32. doi: 10.1002/stem.1056.

30.

Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.

Pellegatta S, Cuppini L, Finocchiaro G.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1759-74. doi: 10.1586/era.11.102. Review.

PMID:
22050025
31.

Immunotherapy for glioma: getting closer to the clinical arena?

Finocchiaro G, Pellegatta S.

Curr Opin Neurol. 2011 Dec;24(6):641-7. doi: 10.1097/WCO.0b013e32834cbb17. Review.

PMID:
22027543
32.

DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.

Menghi F, Orzan FN, Eoli M, Farinotti M, Maderna E, Pisati F, Bianchessi D, Valletta L, Lodrini S, Galli G, Anghileri E, Pellegatta S, Pollo B, Finocchiaro G.

Oncologist. 2011;16(10):1440-50. doi: 10.1634/theoncologist.2010-0249. Epub 2011 Sep 23.

33.

A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.

Cantini G, Pisati F, Mastropietro A, Frattini V, Iwakura Y, Finocchiaro G, Pellegatta S.

Cancer Immunol Immunother. 2011 Dec;60(12):1739-50. doi: 10.1007/s00262-011-1069-4. Epub 2011 Jul 21.

PMID:
21779877
34.

Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.

Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G.

Neuropathol Appl Neurobiol. 2011 Jun;37(4):381-94. doi: 10.1111/j.1365-2990.2010.01132.x.

PMID:
20946108
35.

Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.

Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F, Ravanini M, Finocchiaro G.

Neuro Oncol. 2010 Apr;12(4):377-88. doi: 10.1093/neuonc/nop024. Epub 2010 Jan 6.

36.

Reelin affects chain-migration and differentiation of neural precursor cells.

Massalini S, Pellegatta S, Pisati F, Finocchiaro G, Farace MG, Ciafrè SA.

Mol Cell Neurosci. 2009 Dec;42(4):341-9. doi: 10.1016/j.mcn.2009.08.006. Epub 2009 Aug 19.

PMID:
19698788
37.

Dendritic cell vaccines for cancer stem cells.

Pellegatta S, Finocchiaro G.

Methods Mol Biol. 2009;568:233-47. doi: 10.1007/978-1-59745-280-9_15.

PMID:
19582431
38.

The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy.

Tunici P, Pellegatta S, Finocchiaro G.

Cytotechnology. 2003 Mar;41(2-3):93-101. doi: 10.1023/A:1024818621377.

39.

Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG, Finocchiaro G.

Cancer Res. 2006 Nov 1;66(21):10247-52.

40.

Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.

Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F, Baggi F, Bruzzone MG, Finocchiaro G.

Neurol Res. 2006 Jul;28(5):527-31.

PMID:
16808884
41.

The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation.

Pellegatta S, Tunici P, Poliani PL, Dolcetta D, Cajola L, Colombelli C, Ciusani E, Di Donato S, Finocchiaro G.

Neurobiol Dis. 2006 Feb;21(2):314-23. Epub 2005 Sep 30.

PMID:
16199167
42.

Cell therapies in neuro-oncology.

Pellegatta S, Finocchiaro G.

Neurol Sci. 2005 May;26 Suppl 1:S43-5.

PMID:
15883693
43.

Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.

Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A.

Tissue Antigens. 2002 Apr;59(4):273-9.

PMID:
12135425

Supplemental Content

Loading ...
Support Center